cGxP.wire https://validator.w3.org/feed/docs/rss2.html AbbVie Reports Positive Phase 2 Zumilokibart Atopic Dermatitis Results Takeda Reports Phase 3 Zasocitinib Psoriasis Results Oncolytics Reports Pelareorep Data Supporting Immune Activation in Liver Cancer Boehringer Ingelheim Commits €500M to Health and Sustainability Dyne Therapeutics Reports One-Year Z-Basivarsen Data in DM1 Zealand Pharma Reports Petrelintide Phase 2 ZUPREME-1 Data Akeso Advances Cadonilimab in Global Gastric Cancer Trial DBV Technologies Submits BLA for VIASKIN Peanut Patch GPN Vaccines Advances Serotype-Independent Bacterial Vaccine Platform AnaCardio Raises €62.5 Million Series B for AC01 Roche Gains FDA Priority Review for Fenebrutinib in Multiple Sclerosis Egle Therapeutics Reports Phase 1 EGL-003 Treg Expansion Data Eli Lilly Reports Zepbound Weight-Loss Comparison Data Italfarmaco Reports Long-Term Givinostat Upper Limb Data in DMD Hummingbird Bioscience Doses First Patient in HMBD-001 Phase II Trial VectorY Expands PIONEER-ALS Trial to 36 Participants Aldeyra Plans FDA Dispute Resolution Request for Reproxalap Novo Nordisk Reports Ozempic Cardiovascular Real-World Data AbbVie Highlights Dermatology Research at 2026 EADV Congress Kodiak Sciences Reports Positive Phase 3 Zenkuda Results Innovent Biologics Advances IBI363 in Global Cancer Trials AbbVie Partners With Valkai to Advance AI in Clinical Development Teva Wins FDA Approval for DEGEVMA Biosimilar to Xgeva Ascletis Pharma Reports Positive ASC50 Psoriasis Trial Results Novo Nordisk and Hengrui Pharma Sign $2.6B License Deal Goldenrod Advances 11h Alzheimer’s Research Collaboration Zai Lab to Present Global Zoci Data in First-Line ES-SCLC Nurix Therapeutics Reaches $7 Million Pfizer Collaboration Milestone Immix Biopharma Reports 89% Complete Response Rate With NXC-201 Navigator Medicines Presents NAV-240 and NAV-242 Data at EADV 2026 Castle Biosciences Advances Barrett’s Risk Testing With TissueCypher Invivyd Reports Positive Phase 3 LIBERTY Data for VYD2311 PolarityBio to Present Phase 3 SkinTE Data at SAWC Fall 2026 uniQure Reports 48-Month AMT-130 Data in Huntington’s Disease Cellectar Reports Iopofosine I 131 Data in BTKi-Refractory Waldenström Macroglobulinemia Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA Cartesian Reports Durable Descartes-08 Retreatment Data in MG Cognition Therapeutics Schedules FDA Type C Meeting for Zervimesine JCR Gains Japan Orphan Drug Designation for Givinostat Acadia Gains U.S. Patent Allowance for Trofinetide Dosing Verastem Reports Two-Year RAMP 201 Data in LGSOC Eccogene Receives $50M Milestone After Elecoglipron Phase 3 Start AstraZeneca Invests $2 Billion in Summit Therapeutics Kither Biotech Doses First Patients in KIT2014 COPD Trial Cyprumed Oral Delivery Technology Enters Clinical Stage With MSD TransCode Advances TTX-MC138 in Phase 1a Cancer Trial Lakewood-Amedex Reports Positive Nu-3 Antimicrobial Data SetPoint Medical Expands RA Neuroimmune Therapy Access AbbVie Wins FDA Approval for JUVMO in Parkinson’s Disease Caspian Unveils KO-7246 Preclinical Diabetes Data at EASD